MOLECULAR SUBTYPING, PROGNOSIS, AND TREATMENT OF BLADDER CANCER

Patent №

US 11,208,697

Granted

2021-12-28

Filed 2018

Owner

GENOMEDX BIOSCIENCES, INC.

+4 more

Lab

AI components

2

nlp · kr

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

15875871

The present invention relates to methods, systems and kits for the diagnosis, prognosis, and treatment of bladder cancer in a subject. The invention also provides biomarkers that define subgroups of bladder cancer, clinically useful classifiers for distinguishing bladder cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping bladder cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping bladder cancer in a subject. Classifiers for subtyping a bladder cancer are provided. Methods of treating bladder cancer based on molecular subtyping are also provided.

Natural languageKnowledge representationC12Q 1/6886C12Q 1/6811G16H 20/10G16H 20/40G16H 50/20G16H 50/30G16H 50/50G16H 50/70+6 more

AI classification

Knowledge representation0.90
Natural language0.82
Vision0.23
Machine learning0.05
Planning0.00
AI hardware0.00
Evolutionary computation0.00
Speech0.00

Ownership

GENOMEDX BIOSCIENCES, INC.

assignment · 456040148

DECIPHER BIOSCIENCES, INC.

namechg · 485390776

GENOMEDX INC.

namechg · 485390868

THE UNIVERSITY OF BRITISH COLUMBIA

assignment · 515350611

VERACYTE SD, INC.

namechg · 656270138

Assignors

DAVICIONI, ELAI, ASHAB, HUSSAM AL-DEEN, ERHO, NICHOLAS, BLACK, PETER

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC